Since 2012, the Cancer Research Institute has partnered with MedImmune, a member of the AstraZeneca Group, to advance clinical trials to test novel combinations of cancer immunotherapies. CRI is conducting trials using investigational drugs that MedImmune has provided through this partnership from its product pipeline.
AstraZeneca’s support of educational programming includes funding the 2017 Immunotherapy Patient Summit series and multi-year funding for Cancer Immunotherapy Month. Additionally, AstraZeneca provided multi-year support for the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and Annual Awards Dinner. AstraZeneca has also supported the CRI Irvington Postdoctoral Fellowship Program.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
July is Sarcoma Awareness Month. As a rare and difficult-to-treat form of cancer, effective drug treatments are urgently needed and immunotherapy for sarcoma shows promise.
Dr. Joan Levy, director of research at the Chordoma Foundation, discusses the current state of chordoma research and the recently launched partnership with CRI.